Brain Cancer
Diffuse Astrocytoma
Female, 50 years
Patient Internal 9522929
ICD-10 code
C71.1 Malignant Neoplasm of Frontal Lobe
Diagnosis (Incl. Metastases/Stage) and Year
August 2022
Diffuse Astrocytoma, G4 according to WHO, IDH(+) ATRX(+), TP53(+), no MGMT Methylation, Ki67 – 30%.
Previous Treatment
Surgery, Radiation Therapy, Chemotherapy (Temozolomide), Target Therapy (Bevacizumab).
Prognosis and Survival Expectation
The prognosis remains poor, with a median survival of ~14 months from diagnosis.
Treatment Provided
Autologous DCV (5 doses) and CIK (4 doses) over a period of 3 months. Additionally, the patient received nasal drops of Exosomes with Paclitaxel.
Patient Survival/Condition and Year
Date of Review: 15/10/2023
The patient has survived for 14 months since the diagnosis. It can be concluded that the addition of Immunotherapy, alongside Surgery, Radiation Therapy, Chemotherapy and Target Therapy, has exceeded the median survival. She is under the care of her husband. Her condition is stable, but requires assistance for daily needs.
